High glucose and Nε-(carboxymethyl) lysine bovine serum albumin modulate release of matrix metalloproteinases in cultured human endothelial cells

European Journal of Nutrition

Volumn 45, Issue 5, 2006, Pages 283-290

  Gharagozlian, Sedegheh ^a,b   Henriksen, Tore ^c   Kolset, Svein Olav ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b AKER UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Advanced glycation end products (AGEs); Diabetes; Endothelial cells; Hyperglycaemia; Matrix metalloproteinases

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; BOVINE SERUM ALBUMIN; GELATINASE A; GELATINASE B; GLUCOSE; PHORBOL 13 ACETATE 12 MYRISTATE; MATRIX METALLOPROTEINASE; SERUM ALBUMIN;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VITRO STUDY; INFANT; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN SECRETION; PROTEIN SYNTHESIS; UMBILICAL CORD; WESTERN BLOTTING; ZYMOGRAPHY; CYTOLOGY; DOSE RESPONSE; ENZYMOLOGY; HYPERGLYCEMIA; METABOLISM; PATHOPHYSIOLOGY; SECRETION;

BOS TAURUS;

BLOTTING, WESTERN; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASES; SERUM ALBUMIN; UMBILICAL CORD;

EID: 33746674438     PISSN: 14366207     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00394-006-0597-8     Document Type: Article

References (37)

1. (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977-986
2. (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837-853
3. Ikeda K, Higashi T, Sano H. et al. (1996) N (epsilon)-(carboxymethyl) lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry (Mosc) 35:8075-8083
4. Wendt T, Tanji N, Guo J. et al. (2003) Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 14:1383-1395
5. Vlassara H, Cai W, Crandall J. et al. (2002) Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 99:15596-15601
6. Raj DS, Choudhury D, Welbourne TC, Levi M (2000) Advanced glycation end products: a Nephrologist's perspective. Am J Kidney Dis 35:365-380
7. Ko SH, Hong OK, Kim JW, Ahn YB, Song KH, Cha BY, Son HY, Kim MJ, Jeong IK, Yoon KH (2006) High glucose increases extracellular matrix production in pancreatic stellate cells by activating the renin-angiotensin system. J Cell Biochem [Epub ahead of print]
8. Vogl-Willis CA, Edwards IJ (2004) High-glucose-induced structural changes in the heparan sulfate proteoglycan, perlecan, of cultured human aortic endothelial cells. Biochim Biophys Acta 1672(Apr 7, 1):36-45
9. McGinn S, Poronnik P, Gallery ED, Pollock CA (2004) The effects of high glucose and atorvastatin on endothelial cell matrix production. Diabet Med 21(10):1102-1107
10. Ha H, Lee HB (2005) Reactive oxygen species amplify glucose signalling in renal cells cultured under high glucose and in diabetic kidney. Nephrology (Carlton) 10(Suppl (Carlton)):S7-S10
11. Wolf G, Chen S, Ziyadeh FN (2005) From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 54(6):1626-1634
12. Thomas MC, Forbes JM, Cooper ME (2005) Advanced glycation end products and diabetic nephropathy. Am J Ther 12(6):562-572
13. Paul RG, Bailey AJ (1999) The effect of advanced glycation end-product formation upon cell-matrix interactions. Int J Biochem Cell Biol 31:653-660
14. Pedchenko VK, Chetyrkin SV, Chuang P, Ham AJ, Saleem MA, Mathieson PW, Hudson BG, Voziyan PA (2005) Mechanism of perturbation of integrin-mediated cell-matrix interactions by reactive carbonyl compounds and its implication for pathogenesis of diabetic nephropathy. Diabetes 54(10):2952-2960
15. Furness PN (1997) Basement membrane synthesis and degradation. J Pathol 183:1-3
16. Jackson CJ, Nguyen M (1997) Human microvascular endothelial cells differ from macrovascular endothelial cells in their expression of matrix metalloproteinases. Int J Biochem Cell Biol 29:1167-1177
17. Huang Y, Song L, Wu S, Fan F, Lopes-Virella MF (2001) Oxidized LDL differentially regulates MMP-1 and TIMP-1 expression in vascular endothelial cells. Atherosclerosis 156(1):119-125
18. Kong YZ, Huang XR, Ouyang X, Tan JJ, Fingerle-Rowson G, Bacher M, Mu W, Scher LA, Leng L, Bucala R, Lan HY (2001) Evidence for vascular macrophage migration inhibitory factor in destabilization of human atherosclerotic plaques. Cardiovasc Res 65(1):272-282
19. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, CesareD De, BlasisG De, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A (2002) The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 108(9):1070-1077
20. Shah PK, Falk E, Badimon JJ. et al. (1995) Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 92:1565-1569
21. Shah PK, Galis ZS (2001) Matrix metalloproteinase hypothesis of plaque rupture: players keep piling up but questions remain. Circulation 104:1878-1880
22. Borrebaek J, Prydz K, Fjeldstad K et al. (2001) The AGE product N epsilon-(carboxymethyl)lysine serum albumin is a modulator of proteoglycan expression in polarized cultured kidney epithelial cells. Diabetologia 44:488-494
23. Winberg JO, Kolset SO, Berg E, Uhlin-Hansen L (2000) Macrophages secrete matrix metalloproteinase 9 covalently linked to the core protein of chondroitin sulphate proteoglycans. J Mol Biol 304:669-680
24. Winberg JO, Berg E, Kolset SO, Uhlin-Hansen L (2003) Calcium-induced activation and truncation of promatrix metalloproteinase-9 linked to the core protein of chondroitin sulfate proteoglycans. Eur J Biochem 270(19):3996-4007
25. Loennechen T, Mathisen B, Hansen J, Lindstad RI, El Gewely SA, Andersen K, Maelandsmo GM, Winberg JO (2003) Colchicine induces membrane-associated activation of matrix metalloproteinase-2 in osteosarcoma cells in an S100A4- independent manner. Biochem Pharmacol 66:2341-2353
26. Mathisen B, Lindstad RI, Hansen J, El Gewely SA, Maelandsmo GM, Hovig E, Fodstad O, Loennechen T, Winberg JO (2003) S100A4 regulates membrane induced activation of matrix metalloproteinase-2 in osteosarcoma cells. Clin Exp Metastasis 20:701-711
27. Gavrieli Y, Sherman Y, Ben Sasson SA (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493-501
28. McLennan SV, Yue DK, Turtle JR (1998) Effect of glucose on matrix metalloproteinase activity in mesangial cells. Nephron 79:293-298
29. Uemura S, Matsushita H, Li W et al. (2001) Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 88:1291-1298
30. Death AK, Fisher EJ, McGrath KC, Yue DK (2003) High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 168:263-269
31. Chen HH, Wang DL (2004) Nitric oxide inhibits matrix metalloproteinase-2 expression via the induction of activating transcription factor 3 in endothelial cells. Mol Pharmacol 65(5):1130-1140
32. Galis ZS (2004) Vulnerable plaque: the devil is in the details. Circulation 110(Jul 20, 3):244-246
33. Galis ZS, Khatri JJ (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90(3):251-262
34. Haas TL (2005) Endothelial cell regulation of matrix metalloproteinases. Can J Physiol Pharmacol 83(1):1-7
35. Singh R, Song RH, Alavi N, Pegoraro AA, Singh AK, Leehey DJ (2001) High glucose decreases matrix metalloproteinase-2 activity in rat mesangial cells via transforming growth factor-beta1. Exp Nephrol 9(4):249-257
36. McLennan SV, Martell SY, Yue DK (2000) High glucose concentration inhibits the expression of membrane type metalloproteinase by mesangial cells: possible role in mesangium accumulation. Diabetologia 43(5):642-648
37. Dandona P (2002) Endothelium, inflammation, and diabetes. Curr Diab Rep 2:311-315